Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

Market Cap	2.19B +1.2%
Revenue (ttm)	193.05M +53.4%
Net Income	-103.28M
EPS	-0.94
Shares Out	109.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	985,719
Average Volume	1,449,450
Open	19.88
Previous Close	19.96
Day's Range	19.72 - 20.16
52-Week Range	17.02 - 33.67
Beta	0.96
RSI	40.25
Earnings Date	Apr 24, 2026

About Jiangsu CoWin Biotech

Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and protection, PCR, RT-PCR, and qPCR products, molecular diagnosis, isothermal amplification, nucleic acid mass spectrometry, next generation sequencing, nu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 770
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688426

Financial Performance

In 2025, Jiangsu CoWin Biotech's revenue was 193.05 million, an increase of 53.36% compared to the previous year's 125.88 million. Losses were -103.28 million, -34.30% less than in 2024.